DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
A•••••• B••••••••• I••
Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
102¢ · 105¢ · 105¢ · 105¢ · 105¢Q2 2025 to Q2 2026
Where each lender marks it, 0 points apart
105¢105¢
Principal held
at least $48.8M
sum of BDC pieces, a lower bound
Fair value
$54.2M
105c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
3
3 on the latest quarter
Facilities
2
0 equity pieces beside them
Next maturity
Aug 31, 2029
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
4
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| S•• I••••••••• C•••• | $33.4M | 105¢ | 0 pts |
| S•• P•••••• C••••• I••••• B•• L•• | $12.3M | 105¢ | 0 pts |
| S•• H• B•• L•• | $3.14M | 105¢ | 0 pts |
Every BDC piece · 3 positions across 3 lenderslargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| S•• I••••••••• C•••• | term loan first lien | F•••• L••• L••• S•••••• S••••• S•••••• L•••• | 12/2021 | 8/2029 | $33.4M | $37.1M 105c | SOFR+595 bp |
| S•• P•••••• C••••• I••••• B•• L•• | term loan first lien I••••••• P••••••••• S••••• above I•••• S+595 F•••• 2.50% I••••••• R••• 9.57% A••••••••• D• | $12.3M | $13.6M 105c | SOFR+595 bp |
| S•• H• B•• L•• | term loan first lien B••• D•••/S••••• S•••••• L•••• | 12/2021 | 8/2029 | $3.1M | $3.5M 105c | SOFR+595 bp |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $48.8M | 105c | SOFR+595 bp | Aug 31, 2029 | 3 |
| other lien unstated exited Dec 31, 2022 | at least $24.5M | 101c | S+745 bp | Jan 1, 2027 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 3 | $48.8M | $54.2M | 105c | 0 |
| Mar 31, 2026 | 3 | $48.8M | $54.0M | 105c | 0 |
| Dec 31, 2025 | 3 | $48.8M | $53.8M | 105c | 0 |
| Sep 30, 2025 | 3 | $48.8M | $53.5M | 105c | 0 |
All 13 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 3 | $48.8M | $51.7M | 102c | 0 |
| Mar 31, 2025 | 3 | $48.8M | $51.6M | 102c | 0 |
| Dec 31, 2024 | 3 | $110M | $116M | 102c | 0 |
| Sep 30, 2024 | 3 | $97.7M | $103M | 103c | 0 |
| Jun 30, 2024 | 3 | $97.7M | $103M | 102c | 0 |
| Mar 31, 2024 | 3 | $97.7M | $103M | 103c | 0 |
| Dec 31, 2023 | 3 | $244M | $249M | 100c | 0 |
| Sep 30, 2023 | 3 | $97.7M | $99.4M | 100c | 0 |
| Dec 31, 2022 | 3 | $195M | $198M | 101c | 0 |
What changed
- Spread changed (observed)Sep 30, 2024
- Maturity extended (observed)Sep 30, 2024
- Maturity extended (observed)Sep 30, 2024
- Maturity extended (observed)Sep 30, 2024
- Maturity extended (observed)Sep 30, 2024
Full timeline · 7 eventsShow fewer
- New borrower on a BDC scheduleDec 31, 2022
- Facility left every BDC scheduleDec 31, 2022
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- A•••••• B•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 3 BDCsderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it